Target intelligence / Profile preview

Plasmodium falciparum mitochondrial cytochrome bc1 complex

Molecular classification
Enzyme, Mitochondrial respiratory chain protein, Electron transport chain complex
01

Overview

The Plasmodium falciparum mitochondrial cytochrome bc1 complex (Complex III) is a multisubunit enzyme involved in the parasite's mitochondrial respiratory chain. It catalyzes the transfer of electrons from ubiquinol to cytochrome c, coupling this to the translocation of protons across the inner mitochondrial membrane. This process is fundamental for maintaining the mitochondrial membrane potential and for energy production (ATP synthesis). In Plasmodium falciparum, cytochrome bc1 is also crucial for regenerating ubiquinone, which is required for dihydroorotate dehydrogenase activity and, therefore, for pyrimidine biosynthesis. The complex is a validated target for antimalarial drugs such as atovaquone; inhibitors of bc1 disrupt the parasite's energy metabolism and have lethal effects. However, mutations in the cytochrome b subunit can confer resistance to these inhibitors, posing challenges for treatment and drug development[1][2][3][5].

Other names
Cytochrome bc1 complexComplex IIIubiquinol-cytochrome c oxidoreductaserespiratory Complex IIIcyt bc1
02

Mechanism of action

Inhibition of electron transfer from ubiquinol to cytochrome c - Disruption/collapse of mitochondrial membrane potential - Inhibition of de novo pyrimidine biosynthesis (by halting oxidative recycling of ubiquinone, thereby blocking dihydroorotate dehydrogenase)

03

Biological functions

Electron transport (respiratory chain)Oxidative phosphorylationGeneration of proton gradient (proton motive force)Pyrimidine biosynthesis (via regeneration of ubiquinone for dihydroorotate dehydrogenase)
04

Disease associations

Infection (critical for survival of malaria parasite Plasmodium falciparum)
05

Safety considerations

Development of drug resistance via mutations in cytochrome bSelectivity and cytotoxicity (potential for toxicity to human mitochondrial Complex III; needs careful drug design to ensure parasite selectivity)
06

Interacting drugs

Atovaquone

3 more in the full profile.

07

Biomarkers

Mutations in cytochrome b (e.g., atovaquone resistance-conferring mutations such as M221Q, K228M, etc.)

Beyond the preview

Go deeper on Plasmodium falciparum mitochondrial cytochrome bc1 complex.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Plasmodium falciparum mitochondrial cytochrome bc1 complex.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call